The effects of Enalapril and Irbesartan in experimental diabetic nephropathy

Basit Öğe Kaydı
dc.authoridPuyan, Fulya/0000-0001-5853-0109
dc.authoridOz Puyan, Fulya/0000-0001-5853-0109
dc.authorwosidPuyan, Fulya/V-7074-2019
dc.authorwosidOz Puyan, Fulya/A-7077-2018
dc.contributor.authorYalcin, O.
dc.contributor.authorUstundag, S.
dc.contributor.authorSen, S.
dc.contributor.authorUsta, U.
dc.contributor.authorHuseyinova, G.
dc.contributor.authorPuyan, F. Oz
dc.contributor.authorKutlu, K.
dc.date.accessioned2024-06-12T10:59:28Z
dc.date.available2024-06-12T10:59:28Z
dc.date.issued2007
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIn our study we investigated the effects of angiotensin converting enzyme inhibitor and Angiotensin T, receptor blocker at low-doses which do not affect blood pressure and renal hemodynamia on the experimental diabetic nephropathy. Diabetes mellitus was induced by 50 mg/kg streptozotocin on Sprague-Dawley rats. Except for the patient control group, 2.5 mg/kg Enalapril (an angiotensin converting enzyme inhibitor) and 5 mg/kg Irbesartan (an Angiotensin T, receptor blocker) were given everyday via drinking water during six weeks period. After 24-hour urine collection, blood was withdrawn by cardiac puncture, and rats were sacrificed. Renal functions, histopathologic and electron microscopic alterations in renal tissues, and relative percent deposition of type IV Collagen were investigated. Diabetic nephropathy was determined with the increase of plasma glucose, HbA(9)C (P< 0. 000), urea, creatinin (P<0.005) and urinary protein, albumin, glucose (P<0. 000) inpatient control and Enalapril and Irbesartan treatment groups when compared to the healthy control group. Mesangiocellular proliferation, tubular basement membrane thickness, percentage of glomerular collagen accumulation reduced in treatment groups and glucose in urine in Enalapril group declined. Our findings suggest that renal protective effects of Enalapril and Irbesartan in the development of diabetic nephropathy were comparable.en_US
dc.identifier.doi10.1080/13102818.2007.10817475
dc.identifier.endpage371en_US
dc.identifier.issn1310-2818
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-34548838057en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage366en_US
dc.identifier.urihttps://doi.org/10.1080/13102818.2007.10817475
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20458
dc.identifier.volume21en_US
dc.identifier.wosWOS:000254704400018en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherDiagnosis Press Ltden_US
dc.relation.ispartofBiotechnology & Biotechnological Equipmenten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDiabetic Nephropathyen_US
dc.subjectDiabetes Mellitusen_US
dc.subjectType IV Collagen Depositionen_US
dc.subjectEnalaprilen_US
dc.subjectIrbesartanen_US
dc.subjectNitric-Oxide Synthaseen_US
dc.subjectAngiotensin-Iien_US
dc.subjectGlomerular Hyperfiltrationen_US
dc.subjectReceptor Antagonistsen_US
dc.subjectAce-Inhibitorsen_US
dc.subjectDiseaseen_US
dc.subjectPathogenesisen_US
dc.subjectMechanismsen_US
dc.subjectLosartanen_US
dc.titleThe effects of Enalapril and Irbesartan in experimental diabetic nephropathyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu